<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04987671</url>
  </required_header>
  <id_info>
    <org_study_id>A35-005</org_study_id>
    <nct_id>NCT04987671</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS</brief_title>
  <official_title>A Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amylyx Pharmaceuticals Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amylyx Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic effect after&#xD;
      a single dose or at steady state after multiple doses of AMX0035 in adults with sporadic ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AMX0035 is a proprietary combination of two small molecules, phenylbutyrate (PB) and&#xD;
      taurursodiol. The combination of PB and taurursodiol in AMX0035 is intended to block neuronal&#xD;
      death and neurotoxic inflammation through simultaneous reduction of endoplasmic reticulum&#xD;
      (ER) stress and mitochondrial stress. The pharmacokinetic of AMX0035 has been evaluated in&#xD;
      healthy volunteers. This Phase IIa trial is intended to evaluate pharmacokinetic of PB and&#xD;
      taurursodiol upon single dose multiple dose administration of AMX0035 in patients with ALS.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 5, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood concentration of PB and taurursodiol</measure>
    <time_frame>Between Day 1 and Day 40</time_frame>
    <description>Maximum plasma concentration - Cmax of PB and taurursodiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Systemic exposure to PB and taurursodiol</measure>
    <time_frame>Between Day 1 and Day 40</time_frame>
    <description>Area under the plasma concentration versus time curve - AUC of PB and taurursodiol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of demographic characteristics on blood concentration of PB and taurursodiol</measure>
    <time_frame>Between Day 1 and Day 40</time_frame>
    <description>Maximum plasma concentration - Cmax of PB and taurursodiolin relation to gender, body weight and age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of demographic characteristics on systemic exposure of PB and taurursodiol</measure>
    <time_frame>Between Day 1 and Day 40</time_frame>
    <description>Area under the plasma concentration versus time curve - AUC of PB and taurursodiol relation to gender, body weight and age.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of a fixed dose combination of sodium phenyl butyrate (PB) and taurursodiol on pharmacodynamic activity</measure>
    <time_frame>Between Day 1 and Day 40</time_frame>
    <description>Histone 3 and histone 4 acetylation levels in peripehral blood mononuclear cells (PBMC)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>ALS</condition>
  <arm_group>
    <arm_group_label>Treatment with AMX0035</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two sequential study period. In Period 1, subject receive AMX0035 daily for approximately 14 days. In Period 2, subjects receive AMX0035 twice a day, morning and evening, for up to 25 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMX0035</intervention_name>
    <description>Fixed dose combination of Sodium Phenylbutyrate and taurursodiol.</description>
    <arm_group_label>Treatment with AMX0035</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, &gt;=18years of age;&#xD;
&#xD;
          2. Diagnosis of sporadic ALS (definite, probable, laboratory probable, possible) made by&#xD;
             physician experienced with management of ALS as defined by the World Federation of&#xD;
             Neurology revised El Escorial criteria;&#xD;
&#xD;
          3. If taking riluzole, must be on a stable dose for &gt;30 days prior to Day 1 and&#xD;
             anticipated to remain at that dose until the final study visit.&#xD;
&#xD;
          4. If taking edaravone, must be on a stable regimen for &gt; 30 days prior to Day 1 and&#xD;
             infusion(s) can be scheduled to be performed at no less than 48 hours prior or after&#xD;
             the planned pharmacokinetic and pharmacodynamic (PK/PD) sampling.&#xD;
&#xD;
          5. Capable of providing informed consent and following trial procedures;&#xD;
&#xD;
          6. Geographically accessible to the site;&#xD;
&#xD;
          7. Able to undergo the study procedures (including planned sampling on 3 occasions) and&#xD;
             to adhere to the visit schedule, as determined by Investigator;&#xD;
&#xD;
          8. Women of child bearing potential (e.g. not post-menopausal for at least one year or&#xD;
             surgically sterile) must agree to use adequate birth control for the duration of the&#xD;
             study and 3 months after last dose of study drug;&#xD;
&#xD;
             a. Women must not be planning to become pregnant for the duration of the study and 3&#xD;
             months after last dose of study drug&#xD;
&#xD;
          9. Men must agree to practice contraception for the duration of the study and for at&#xD;
             least 3 months after last dose of study drug;&#xD;
&#xD;
               1. Men must not plan to father a child or provide sperm for donation for the&#xD;
                  duration of the study and 3 months after last dose of study drug&#xD;
&#xD;
               2. Acceptable birth control methods for use in this study are:&#xD;
&#xD;
                    -  Hormonal methods, such as birth control pills, patches, injections, vaginal&#xD;
                       ring, or implants&#xD;
&#xD;
                    -  Barrier methods (such as a condom or diaphragm) used with a spermicide (a&#xD;
                       foam, cream, or gel that kills sperm)&#xD;
&#xD;
                    -  Intrauterine device (IUD)&#xD;
&#xD;
                    -  Abstinence (no heterosexual sex)&#xD;
&#xD;
                    -  Unique partner who is surgically sterile (men) or not of child bearing&#xD;
                       potential (female)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Familial ALS&#xD;
&#xD;
          2. Forced vital capacity &lt; 50% (or alternatively SVC) or presence of tracheostomy or&#xD;
             under PAV (PAV is defined as more than 22 hours daily of non-invasive mechanical&#xD;
             ventilation for more than 7 days);&#xD;
&#xD;
          3. Planned elective surgery (such as feeding tube or edaravone access port placement)&#xD;
             during the duration of the study;&#xD;
&#xD;
          4. History of known allergy to PB or bile salts;&#xD;
&#xD;
          5. Abnormal liver function defined as aspartate aminotransferase and/or alanine&#xD;
             aminotransferase (AST and/or ALT) &gt; 3 times the upper limit of the normal;&#xD;
&#xD;
          6. Renal insufficiency as defined by eGFR &lt; 60 mL/min/1.73m2;&#xD;
&#xD;
          7. Ongoing Anemia with Hg concentration &lt; 10.0 g/dL&#xD;
&#xD;
          8. Pregnant women or women currently breastfeeding;&#xD;
&#xD;
          9. Current biliary disease which may lead to biliary obstruction or impedes biliary flow&#xD;
             including active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis,&#xD;
             gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the&#xD;
             gallbladder;&#xD;
&#xD;
         10. History of Class III/IV heart failure (per New York Heart Association - NYHA);&#xD;
&#xD;
         11. Patient under severe salt restriction where the added salt intake due to treatment&#xD;
             would put the patient at risk, in the Site Investigator clinical judgement;&#xD;
&#xD;
         12. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance&#xD;
             abuse that would impair ability of the subject to provide informed consent, according&#xD;
             to Site Investigator judgment;&#xD;
&#xD;
         13. Presence of an active infection requiring systemic antiviral or antimicrobial therapy&#xD;
             at any time during the screening period.&#xD;
&#xD;
         14. Clinically significant unstable medical condition (other than ALS) that would pose a&#xD;
             risk to the subject if they were to participate in the study, according to Site&#xD;
             Investigator judgment.&#xD;
&#xD;
         15. Clinically significant, as determined by the Investigator, 12-lead ECG abnormalities&#xD;
             at screening.&#xD;
&#xD;
         16. Treatment, current or within 90 days from start of study treatment, with any cell&#xD;
             therapies or gene therapies;&#xD;
&#xD;
         17. Treatment, current or within 90 days from start of study treatment, with experimental&#xD;
             medication (for ALS or other indications)&#xD;
&#xD;
         18. Current or anticipated need for a Diaphragm Pacing System (DPS);&#xD;
&#xD;
         19. Anything that, in the opinion of the Site Investigator preclude the subject's full&#xD;
             compliance with or completion of the study;&#xD;
&#xD;
         20. Exposure to any disallowed medications listed below:&#xD;
&#xD;
               1. HDAC Inhibitors including:&#xD;
&#xD;
                    -  Valproate&#xD;
&#xD;
                    -  Vorinostat (Zolinza)&#xD;
&#xD;
                    -  Romidepsin&#xD;
&#xD;
                    -  Chidamide&#xD;
&#xD;
                    -  Panobinostat&#xD;
&#xD;
                    -  Lithium&#xD;
&#xD;
                    -  Butyrate&#xD;
&#xD;
                    -  Suramin&#xD;
&#xD;
               2. Probenecid&#xD;
&#xD;
               3. Bile Acid Sequestrants including:&#xD;
&#xD;
                    -  Cholestyramine and Cholestyramine Light&#xD;
&#xD;
                    -  Questran and Questran Light&#xD;
&#xD;
                    -  Welchol&#xD;
&#xD;
                    -  Colestid and Colestid Flavored&#xD;
&#xD;
                    -  Prevalite&#xD;
&#xD;
               4. Product that may interact with sterol absorption or excretion&#xD;
&#xD;
                    -  Ezetimibe&#xD;
&#xD;
               5. Note on Antacids within Two Hours of AMX0035 Administration: Antacids containing&#xD;
                  aluminum hydroxide or smectite (aluminum oxide) may not be taken within two hours&#xD;
                  of administration of MX0035 as they inhibit absorption of taurursodiol. These&#xD;
                  include:&#xD;
&#xD;
                    -  Alamag&#xD;
&#xD;
                    -  Alumina and Magnesia&#xD;
&#xD;
                    -  Antacid, Antacid M and Antacid Suspension&#xD;
&#xD;
                    -  Gen-Alox&#xD;
&#xD;
                    -  Kudrox&#xD;
&#xD;
                    -  M.A.H.&#xD;
&#xD;
                    -  Maalox HRF and Maalox TC&#xD;
&#xD;
                    -  Magnalox&#xD;
&#xD;
                    -  Maldroxal&#xD;
&#xD;
                    -  Mylanta and Mylanta Ultimate&#xD;
&#xD;
                    -  Ri-Mox&#xD;
&#xD;
                    -  Rulox&#xD;
&#xD;
         21. Clinically significant, in the opinion of the Investigator, infection or inflammation&#xD;
             at time of screening or admission.&#xD;
&#xD;
         22. Acute gastrointestinal symptoms (eg, nausea, vomiting, diarrhea) at time of screening&#xD;
             or admission or a or clinical diagnosis of irritable bowel syndrome (IBS) per ROME&#xD;
             criteria (Appendix 7).&#xD;
&#xD;
         23. Any current or previous illicit use of Class A drugs such as opiates, cocaine,&#xD;
             ecstasy, LSD, and amphetamines (Class B).&#xD;
&#xD;
         24. An alcoholic intake greater than 14 units per week or unwillingness to stop alcohol&#xD;
             consumption for the duration of the study. Note: 1 unit = 8 g ethanol (250 mL of beer&#xD;
             or approximately 10 oz, 1 glass wine [100 mL or approximately 3 oz], 1 measure spirits&#xD;
             [30 mL or approximately 1 oz]).&#xD;
&#xD;
         25. Use of drugs with enzyme inducing properties such as St John's Wort within 3 weeks&#xD;
             prior to the first administration of investigational product.&#xD;
&#xD;
         26. History of plasma/blood donation in the last 2 months.&#xD;
&#xD;
         27. Any condition, which compromises ability to give informed consent or to communicate&#xD;
             with the Investigator as required for the completion of this study.&#xD;
&#xD;
         28. Unwilling to conform to all lifestyle considerations and restrictions mandated by the&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amylyx Trial Operations</last_name>
    <phone>857-320-6222</phone>
    <email>clinicaltrials@amylyx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Norman Fixel Institute for Neurological Diseases</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Steshyn</last_name>
      <phone>352-733-2434</phone>
      <email>Jennifer.steshyn@neurology.ufl.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cuadrado-Tejedor M, Ricobaraza AL, Torrijo R, Franco R, Garcia-Osta A. Phenylbutyrate is a multifaceted drug that exerts neuroprotective effects and reverses the Alzheimer´s disease-like phenotype of a commonly used mouse model. Curr Pharm Des. 2013;19(28):5076-84.</citation>
    <PMID>23448463</PMID>
  </reference>
  <reference>
    <citation>Cudkowicz ME, Andres PL, Macdonald SA, Bedlack RS, Choudry R, Brown RH Jr, Zhang H, Schoenfeld DA, Shefner J, Matson S, Matson WR, Ferrante RJ; Northeast ALS and National VA ALS Research Consortiums. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph Lateral Scler. 2009 Apr;10(2):99-106. doi: 10.1080/17482960802320487.</citation>
    <PMID>18688762</PMID>
  </reference>
  <reference>
    <citation>Nunes AF, Amaral JD, Lo AC, Fonseca MB, Viana RJ, Callaerts-Vegh Z, D'Hooge R, Rodrigues CM. TUDCA, a bile acid, attenuates amyloid precursor protein processing and amyloid-β deposition in APP/PS1 mice. Mol Neurobiol. 2012 Jun;45(3):440-54. doi: 10.1007/s12035-012-8256-y. Epub 2012 Mar 23.</citation>
    <PMID>22438081</PMID>
  </reference>
  <reference>
    <citation>Dionísio PA, Amaral JD, Ribeiro MF, Lo AC, D'Hooge R, Rodrigues CM. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging. 2015 Jan;36(1):228-40. doi: 10.1016/j.neurobiolaging.2014.08.034. Epub 2014 Sep 28.</citation>
    <PMID>25443293</PMID>
  </reference>
  <reference>
    <citation>Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CM, D'Hooge R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol Dis. 2013 Feb;50:21-9. doi: 10.1016/j.nbd.2012.09.003. Epub 2012 Sep 10.</citation>
    <PMID>22974733</PMID>
  </reference>
  <reference>
    <citation>Ricobaraza A, Cuadrado-Tejedor M, Marco S, Pérez-Otaño I, García-Osta A. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus. 2012 May;22(5):1040-50. doi: 10.1002/hipo.20883. Epub 2010 Nov 10.</citation>
    <PMID>21069780</PMID>
  </reference>
  <reference>
    <citation>Ricobaraza A, Cuadrado-Tejedor M, Pérez-Mediavilla A, Frechilla D, Del Río J, García-Osta A. Phenylbutyrate ameliorates cognitive deficit and reduces tau pathology in an Alzheimer's disease mouse model. Neuropsychopharmacology. 2009 Jun;34(7):1721-32. doi: 10.1038/npp.2008.229. Epub 2009 Jan 14.</citation>
    <PMID>19145227</PMID>
  </reference>
  <reference>
    <citation>Rodrigues CM, Solá S, Sharpe JC, Moura JJ, Steer CJ. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry. 2003 Mar 18;42(10):3070-80.</citation>
    <PMID>12627974</PMID>
  </reference>
  <reference>
    <citation>Wiley JC, Pettan-Brewer C, Ladiges WC. Phenylbutyric acid reduces amyloid plaques and rescues cognitive behavior in AD transgenic mice. Aging Cell. 2011 Jun;10(3):418-28. doi: 10.1111/j.1474-9726.2011.00680.x. Epub 2011 Mar 22.</citation>
    <PMID>21272191</PMID>
  </reference>
  <reference>
    <citation>Wright JM, Zeitlin PL, Cebotaru L, Guggino SE, Guggino WB. Gene expression profile analysis of 4-phenylbutyrate treatment of IB3-1 bronchial epithelial cell line demonstrates a major influence on heat-shock proteins. Physiol Genomics. 2004 Jan 15;16(2):204-11.</citation>
    <PMID>14583596</PMID>
  </reference>
  <reference>
    <citation>Zhou W, Bercury K, Cummiskey J, Luong N, Lebin J, Freed CR. Phenylbutyrate up-regulates the DJ-1 protein and protects neurons in cell culture and in animal models of Parkinson disease. J Biol Chem. 2011 Apr 29;286(17):14941-51. doi: 10.1074/jbc.M110.211029. Epub 2011 Mar 3.</citation>
    <PMID>21372141</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>July 15, 2021</study_first_submitted>
  <study_first_submitted_qc>August 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neurodegenerative Diseases</keyword>
  <keyword>Motor Neuron Disease</keyword>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Neuromuscular Diseases</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

